Black Titan (NASDAQ:BTTC) Shares Down 1.9% – Should You Sell?

Black Titan Corp (NASDAQ:BTTC)’s share price traded down 1.9% during mid-day trading on Thursday . The company traded as low as $1.00 and last traded at $1.01. 23,890 shares changed hands during mid-day trading, a decline of 13% from the average session volume of 27,553 shares. The stock had previously closed at $1.03.

Black Titan Trading Down 7.9%

The stock’s 50-day moving average is $1.29. The stock has a market capitalization of $10.02 million, a price-to-earnings ratio of -0.32 and a beta of 1.28.

Institutional Investors Weigh In On Black Titan

Hedge funds and other institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC acquired a new stake in Black Titan in the 4th quarter valued at approximately $26,000. Marex Group plc acquired a new stake in Black Titan in the 4th quarter valued at approximately $84,000. Armistice Capital LLC acquired a new stake in Black Titan in the 4th quarter valued at approximately $840,000. Finally, HRT Financial LP acquired a new stake in Black Titan in the 4th quarter valued at approximately $28,000.

Black Titan Company Profile

Titan Pharmaceuticals, Inc is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.